Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Moderate Buy” by Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $75.00.

A number of equities analysts recently issued reports on the company. Stifel Nicolaus lifted their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. The Goldman Sachs Group upped their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Barclays initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 target price for the company.

Insider Activity

In other Enliven Therapeutics news, Director Lori Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director directly owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44. Following the sale, the chief financial officer directly owned 40,036 shares in the company, valued at approximately $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 186,849 shares of company stock worth $10,998,857 over the last 90 days. 3.00% of the stock is owned by company insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently modified their holdings of ELVN. Dimensional Fund Advisors LP grew its holdings in shares of Enliven Therapeutics by 70.9% during the first quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock valued at $26,714,000 after buying an additional 282,822 shares in the last quarter. Avidity Partners Management LP lifted its stake in Enliven Therapeutics by 185.1% in the 1st quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock worth $15,680,000 after acquiring an additional 259,700 shares in the last quarter. Stempoint Capital LP purchased a new stake in Enliven Therapeutics in the 1st quarter worth about $14,247,000. Tema ETFs LLC boosted its position in Enliven Therapeutics by 41.0% during the 2nd quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock worth $3,080,000 after acquiring an additional 17,638 shares during the period. Finally, TimesSquare Capital Management LLC acquired a new stake in Enliven Therapeutics during the 2nd quarter worth about $13,263,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $59.37 on Wednesday. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of -35.55 and a beta of 0.30. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32. The firm’s 50 day moving average price is $56.00 and its two-hundred day moving average price is $44.77.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, equities analysts predict that Enliven Therapeutics will post -1.69 EPS for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.